Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DC1AV3
|
|||
| Drug Name |
DNL758
|
|||
| Synonyms |
SAR443122
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Cutaneous lupus erythematosus [ICD-11: EB5Z; ICD-10: L80-L99, L93; ICD-9: 710] | Phase 2 | [1] | |
| Company |
Denali Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Receptor-interacting protein 1 (RIPK1) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04781816) Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus (CLEan). U.S. National Institutes of Health. | |||
| REF 2 | Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target. Nat Rev Drug Discov. 2020 Aug;19(8):553-571. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.